Compare Palantir Technologies Inc (PLTR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Palantir Technologies Inc trades at $169.1 (market cap $409.24B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| PLTR | XBI | |
|---|---|---|
Market Cap | $409.24B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $207.18 | $169.55 |
52-Week Low | $107.27 | $93.43 |
Enterprise Value | $400.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir Technologies (PLTR) trades at $170.30, down 2.31% on the day but remains in a strong uptrend with recent earnings beats driving momentum. The stock shows robust fundamentals with 93% revenue growth in Q2 2026 and a 49% net income margin, though valuation metrics remain elevated with a P/E of 145.6. Technical indicators are neutral with support at $168 and resistance at $174, while the recent Nebius partnership strengthens Palantir's sovereign AI positioning.
Palantir's outlook remains positive with strong earnings momentum and strategic AI partnerships, though premium valuation and competitive pressures present risks. The consensus price target of $211.38 suggests 24% upside potential, supported by 50% analyst buy ratings. Key risks include valuation sustainability and compute capacity constraints as demand surges.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
